Research Paper Volume 12, Issue 11 pp 10896—10911

SPTBN1 suppresses the progression of epithelial ovarian cancer via SOCS3-mediated blockade of the JAK/STAT3 signaling pathway


Figure 1. SPTBN1 is closely related to the progression of epithelial ovarian cancer. (A) Analysis of TCGA data. The expression of SPTBN1 was significantly decreased as EOC staging increased. NS: stage 1 vs stage 2, 3, and 4; *P<0.05 vs stage 3 and 4; #P<0.05 vs stage 3. (B, C) The progression-free survival (PFS) and overall survival (OS) rates were retrieved from the TCGA dataset (probe 214856_at) and compared between the low-SPTBN1 and high-SPTBN1 ovarian cancer patients. The low-SPTBN1 group had shorter PFS than the high-SPTBN1 group. (D) Expression of SPTBN1 in 8 ovarian cancer cell lines. The expression of SPTBN1 in high-metastasis HO8910-PM cells was lower than that in conventional HO8910 cells, suggesting that the decrease in SPTBN1 expression may be correlated with the increased incidence of malignancy of epithelial ovarian cancer.